Wird geladen...
Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma
The treatment landscape of metastatic renal cell carcinoma (mRCC) has been transformed with the advent of antiangiogenics, notably tyrosine kinase inhibitors (TKIs) targeting vascular endothelial growth factor receptor (VEGFR), and immune checkpoint inhibitors (ICIs). Both treatment options have imp...
Gespeichert in:
| Veröffentlicht in: | Ther Adv Med Oncol |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
SAGE Publications
2020
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7081462/ https://ncbi.nlm.nih.gov/pubmed/32215057 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835920907504 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|